Marker Therapeutics

MRKR

Market cap $18.7M

MRKR Hedge Fund Activity: Q1 2026 in Review

35 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2026, worth a combined $5.07M — down 16% from $6.03M a quarter earlier.

Fund positioning in MRKR was balanced in Q1 2026: 7 funds opened new positions, 7 closed out, 6 added to existing stakes and 8 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $81.9K. The largest seller was UBS Group, cutting an estimated $225K.

• 35 institutional investors held Marker Therapeutics (MRKR) as of Q1 2026, down from 36 in Q4 2025.
• Funds reported $5.07M of Marker Therapeutics stock for Q1 2026, down 16% quarter-over-quarter.
• 7 funds opened new Marker Therapeutics positions in Q1 2026 and 7 closed out, a net change of 0 holders.
• The largest Marker Therapeutics buyer in Q1 2026 was Renaissance Technologies, an estimated $81.9K added.
• The largest Marker Therapeutics seller in Q1 2026 was UBS Group, an estimated $225K sold.

Based on aggregated 13F filings for Q1 2026.